What is Navidea Biopharmaceuticals EBIT per Share?
Navidea Biopharmaceuticals's EBIT per Share for the
three
months ended in Sep. 2023 was $-0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was $-0.21.
During the past 3 years, the average EBIT per Share Growth Rate was 15.80% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 25.80% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 25.40% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Navidea Biopharmaceuticals's EBIT per Share or its related term are showing as below:
NAVB'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -156.3 Med: 16.05 Max: 44.7
Current: 15.8
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Navidea Biopharmaceuticals was 44.70% per year. The lowest was -156.30% per year. And the median was 16.05% per year.
NAVB's 3-Year EBIT Growth Rate is ranked better than 66.59% of 1305
companies
in the Biotechnology industry
Industry Median: 3.2
vs NAVB: 15.80
Navidea Biopharmaceuticals's EBIT for the
three
months ended in Sep. 2023 was $-2.13 Mil.
Navidea Biopharmaceuticals EBIT per Share Historical Data
The historical data trend for Navidea Biopharmaceuticals's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Navidea Biopharmaceuticals (OTCPK:NAVB) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Navidea Biopharmaceuticals EBIT per Share Related Terms
Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NAVB has been successfully added to your 